Vital Signs The Analyst's Perspective - June 2016 Issue

USD 450

* Required Fields

USD 450

PAY BY INVOICE

Be the first to review this product

This Vital Signs issue discusses Luminex's acquisition of Nanosphere, Medicare's changing approach to paying doctors, Orig3N's partnership with the San Francisco 49ers for collection of blood samples for research, and FDA's halt of Juno Therapeuticss cell therapy trial which left three dead.

Table of Contents

Vital Signs The Analyst's Perspective - June 2016 IssueVital Signs - June 2016 IssueJune 2016 Issue




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 10-Nov-17

Region : Global

Release Date : 10-Nov-17

Region : Global

Release Date : 09-Nov-17

Region : Global

Release Date : 03-Nov-17

Region : Global

Release Date : 31-Oct-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.